SERUM VPR REGULATES PRODUCTIVE INFECTION AND LATENCY OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1

被引:218
|
作者
LEVY, DN [1 ]
REFAELI, Y [1 ]
MACGREGOR, RR [1 ]
WEINER, DB [1 ]
机构
[1] UNIV PENN,DEPT MED,PHILADELPHIA,PA 19104
关键词
D O I
10.1073/pnas.91.23.10873
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
In human immunodeficiency virus (HIV)positive individuals, the vast majority of infected peripheral blood cells and lymph node cells may be latently or nonproductively infected. The vpr open reading frame of HIV-1 encodes a 15-kDa virion-associated protein, Vpr. The vpr gene has been shown to increase virus replication in T cells and monocyte/macrophages in vitro. We have previously reported that vpr expression in various tumor lines leads to growth inhibition and differentiation, indicating that Vpr may function as a regulator of cellular permissiveness to HIV replication. Here we show that Vpr protein is present in significant amounts in the serum of AIDS patients. Purified serum Vpr activated virus expression from five latently infected cell lines, U1, OM.10.1, ACH-2, J1.1, and LL58. Serum Vpr also activated virus expression from resting peripheral blood mononuclear cells of HIV-infected individuals. Together, these findings implicate serum Vpr in the activation of HIV replication in vivo and in the control of latency. Anti-Vpr antibodies inhibited Vpr activity, suggesting that humoral immunity modulates Vpr activity in vivo. These results have broad implications for the virus life cycle and for the prospective control of HIV replication and pathogenesis.
引用
收藏
页码:10873 / 10877
页数:5
相关论文
共 50 条
  • [21] FATE OF THE HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 PROVIRUS IN INFECTED-CELLS - A ROLE FOR VPR
    PLANELLES, V
    BACHELERIE, F
    JOWETT, JBM
    HAISLIP, A
    XIE, YM
    BANOONI, P
    MASUDA, T
    CHEN, ISY
    JOURNAL OF VIROLOGY, 1995, 69 (09) : 5883 - 5889
  • [22] HUMAN MESANGIAL CELLS ARE RESISTANT TO PRODUCTIVE INFECTION BY MULTIPLE STRAINS OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 AND TYPE-2
    ALPERS, CE
    MCCLURE, J
    BURSTEN, SL
    AMERICAN JOURNAL OF KIDNEY DISEASES, 1992, 19 (02) : 126 - 130
  • [23] ANAPLASTIC ASTROCYTOMA IN ASSOCIATION WITH HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 INFECTION
    CARRANA, EJ
    ROSSITCH, E
    MOORE, MR
    FUNKENSTEIN, HH
    AMERICAN JOURNAL OF EMERGENCY MEDICINE, 1990, 8 (06): : 565 - 567
  • [24] LABORATORY TESTS FOR DETECTION OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 INFECTION
    NUWAYHID, NF
    CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY, 1995, 2 (06) : 637 - 645
  • [25] INFECTION BY THE HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 IN THE PRISON POPULATION IN CATALONIA
    BAYAS, JM
    MARTIN, V
    VIDAL, J
    PUMAROLA, T
    DEANTA, MTJ
    SALLERAS, L
    MEDICINA CLINICA, 1994, 102 (06): : 209 - 212
  • [26] PSYCHONEUROIMMUNOLOGY AND HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 INFECTION REVISITED - REPLY
    PERRY, S
    RABKIN, J
    ARCHIVES OF GENERAL PSYCHIATRY, 1994, 51 (03) : 247 - 248
  • [27] MORPHOGENESIS OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1
    CHATTERJEE, S
    BASAK, S
    KHAN, NC
    PATHOBIOLOGY, 1992, 60 (04) : 181 - 186
  • [28] INHIBITION OF INFECTION WITH HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 BY SULFATED GANGLIOSIDES
    HANDA, A
    HOSHINO, H
    NAKAJIMA, K
    ADACHI, M
    IKEDA, K
    ACHIWA, K
    ITOH, T
    SUZUKI, Y
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1991, 175 (01) : 1 - 9
  • [29] INFECTION OF MACACA-NEMESTRINA BY HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1
    AGY, MB
    FRUMKIN, LR
    COREY, L
    COOMBS, RW
    WOLINSKY, SM
    KOEHLER, J
    MORTON, WR
    KATZE, MG
    SCIENCE, 1992, 257 (5066) : 103 - 106
  • [30] TREATMENT TRIALS FOR PRIMARY HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 INFECTION
    NIU, MT
    STEIN, DS
    SCHNITTMAN, SM
    JOURNAL OF INFECTIOUS DISEASES, 1993, 168 (06): : 1601 - 1602